ref_name,rx_name,control_iso_name,iso_name,section,assay_name,potency_type,fold_cmp,fold,resistance_level,ineffective,cumulative_count,date_added
FDA23-NTV,Nirmatrelvir,WA1,3CLpro:T21I,Table 7,Virus isolate,EC50,=,1.1,NULL,NULL,1,2022-09-18
FDA23-NTV,Nirmatrelvir,WA1,3CLpro:L50F,Table 7,Virus isolate,EC50,=,1.5,NULL,NULL,1,2022-09-18
FDA23-NTV,Nirmatrelvir,WA1,3CLpro:F140L,Table 7,Virus isolate,EC50,=,4.1,NULL,NULL,1,2022-09-18
FDA23-NTV,Nirmatrelvir,WA1,3CLpro:S144A,Table 7,Virus isolate,EC50,=,2.2,NULL,NULL,1,2022-09-18
FDA23-NTV,Nirmatrelvir,WA1,3CLpro:E166A,Table 7,Virus isolate,EC50,=,3.3,NULL,NULL,1,2022-09-18
FDA23-NTV,Nirmatrelvir,WA1,3CLpro:E166V,Table 7,Virus isolate,EC50,=,25,NULL,NULL,1,2022-09-18
FDA23-NTV,Nirmatrelvir,WA1,3CLpro:A173V,Table 7,Virus isolate,EC50,=,0.9,NULL,NULL,1,2022-09-18
FDA23-NTV,Nirmatrelvir,WA1,3CLpro:P252L,Table 7,Virus isolate,EC50,=,5.9,NULL,NULL,1,2022-09-18
FDA23-NTV,Nirmatrelvir,WA1,3CLpro:T304I,Table 7,Virus isolate,EC50,=,1.4,NULL,NULL,1,2022-09-18
FDA23-NTV,Nirmatrelvir,WA1,3CLpro:T21I+S144A,Table 7,Virus isolate,EC50,=,9.4,NULL,NULL,1,2022-09-18
FDA23-NTV,Nirmatrelvir,WA1,3CLpro:T21I+E166V,Table 7,Virus isolate,EC50,=,83,NULL,NULL,1,2022-09-18
FDA23-NTV,Nirmatrelvir,WA1,3CLpro:T21I+A173V,Table 7,Virus isolate,EC50,=,3.1,NULL,NULL,1,2022-09-18
FDA23-NTV,Nirmatrelvir,WA1,3CLpro:T21I+T304I,Table 7,Virus isolate,EC50,=,3,NULL,NULL,1,2022-09-18
FDA23-NTV,Nirmatrelvir,WA1,3CLpro:L50F+E166V,Table 7,Virus isolate,EC50,=,34,NULL,NULL,1,2022-09-18
FDA23-NTV,Nirmatrelvir,WA1,3CLpro:L50F+T304I,Table 7,Virus isolate,EC50,=,5.9,NULL,NULL,1,2022-09-18
FDA23-NTV,Nirmatrelvir,WA1,3CLpro:T135I+T304I,Table 7,Virus isolate,EC50,=,3.8,NULL,NULL,1,2022-09-18
FDA23-NTV,Nirmatrelvir,WA1,3CLpro:F140L+A173V,Table 7,Virus isolate,EC50,=,10.1,NULL,NULL,1,2022-09-18
FDA23-NTV,Nirmatrelvir,WA1,3CLpro:A173V+T304I,Table 7,Virus isolate,EC50,=,20.2,NULL,NULL,1,2022-09-18
FDA23-NTV,Nirmatrelvir,WA1,3CLpro:T21I+L50F+A193P+S301P,Table 7,Virus isolate,EC50,=,28.8,NULL,NULL,1,2022-09-18
FDA23-NTV,Nirmatrelvir,WA1,3CLpro:T21I+S144A+T304I,Table 7,Virus isolate,EC50,=,27.8,NULL,NULL,1,2022-09-18
FDA23-NTV,Nirmatrelvir,WA1,3CLpro:T21I+C160F+A173V+V186A+T304I,Table 7,Virus isolate,EC50,=,28.5,NULL,NULL,1,2022-09-18
FDA23-NTV,Nirmatrelvir,WA1,3CLpro:T21I+A173V+T304I,Table 7,Virus isolate,EC50,=,15,NULL,NULL,1,2022-09-18
FDA23-NTV,Nirmatrelvir,WA1,3CLpro:L50F+F140L+L167F+T304I,Table 7,Virus isolate,EC50,=,54.7,NULL,NULL,1,2022-09-18
FDA23-NTV,Nirmatrelvir,WA1,3CLpro:Y54A,In Cell Culture and Biochemical Assays,FRET,Ki,=,25,NULL,NULL,1,2022-09-18
FDA23-NTV,Nirmatrelvir,WA1,3CLpro:F140A,In Cell Culture and Biochemical Assays,FRET,Ki,=,21,NULL,NULL,1,2022-09-18
FDA23-NTV,Nirmatrelvir,WA1,3CLpro:F140L,In Cell Culture and Biochemical Assays,FRET,Ki,=,7.6,NULL,NULL,1,2022-09-18
FDA23-NTV,Nirmatrelvir,WA1,3CLpro:F140S,In Cell Culture and Biochemical Assays,FRET,Ki,=,260,NULL,NULL,1,2022-09-18
FDA23-NTV,Nirmatrelvir,WA1,3CLpro:G143S,In Cell Culture and Biochemical Assays,FRET,Ki,=,3.6,NULL,NULL,1,2022-09-18
FDA23-NTV,Nirmatrelvir,WA1,3CLpro:S144A,In Cell Culture and Biochemical Assays,FRET,Ki,=,46,NULL,NULL,1,2022-09-18
FDA23-NTV,Nirmatrelvir,WA1,3CLpro:S144E,In Cell Culture and Biochemical Assays,FRET,Ki,=,480,NULL,NULL,1,2022-09-18
FDA23-NTV,Nirmatrelvir,WA1,3CLpro:S144T,In Cell Culture and Biochemical Assays,FRET,Ki,=,170,NULL,NULL,1,2022-09-18
FDA23-NTV,Nirmatrelvir,WA1,3CLpro:H164N,In Cell Culture and Biochemical Assays,FRET,Ki,=,6.7,NULL,NULL,1,2022-09-18
FDA23-NTV,Nirmatrelvir,WA1,3CLpro:E166A,In Cell Culture and Biochemical Assays,FRET,Ki,=,35,NULL,NULL,1,2022-09-18
FDA23-NTV,Nirmatrelvir,WA1,3CLpro:E166G,In Cell Culture and Biochemical Assays,FRET,Ki,=,6.2,NULL,NULL,1,2022-09-18
FDA23-NTV,Nirmatrelvir,WA1,3CLpro:E166V,In Cell Culture and Biochemical Assays,FRET,Ki,=,7700,NULL,NULL,1,2022-09-18
FDA23-NTV,Nirmatrelvir,WA1,3CLpro:H172Y,In Cell Culture and Biochemical Assays,FRET,Ki,=,250,NULL,NULL,1,2022-09-18
FDA23-NTV,Nirmatrelvir,WA1,3CLpro:A173S,In Cell Culture and Biochemical Assays,FRET,Ki,=,4.1,NULL,NULL,1,2022-09-18
FDA23-NTV,Nirmatrelvir,WA1,3CLpro:A173V,In Cell Culture and Biochemical Assays,FRET,Ki,=,16,NULL,NULL,1,2022-09-18
FDA23-NTV,Nirmatrelvir,WA1,3CLpro:R188G,In Cell Culture and Biochemical Assays,FRET,Ki,=,38,NULL,NULL,1,2022-09-18
FDA23-NTV,Nirmatrelvir,WA1,3CLpro:Q192L,In Cell Culture and Biochemical Assays,FRET,Ki,=,29,NULL,NULL,1,2022-09-18
FDA23-NTV,Nirmatrelvir,WA1,3CLpro:Q192P,In Cell Culture and Biochemical Assays,FRET,Ki,=,7.8,NULL,NULL,1,2022-09-18
FDA23-NTV,Nirmatrelvir,WA1,3CLpro:V297A,In Cell Culture and Biochemical Assays,FRET,Ki,=,3,NULL,NULL,1,2022-09-18